Jack W. Callicutt
2017
In 2017, Jack W. Callicutt earned a total compensation of $406K as Chief Financial Officer at Galectin Therapeutics, a 19% decrease compared to previous year.
Compensation breakdown
| Bonus | $91,163 |
|---|---|
| Salary | $260,000 |
| Other | $54,848 |
| Total | $406,011 |
Callicutt received $260K in salary, accounting for 64% of the total pay in 2017.
Callicutt also received $91.2K in bonus and $54.8K in other compensation.
Rankings
In 2017, Jack W. Callicutt's compensation ranked 12,567th out of 14,666 executives tracked by ExecPay. In other words, Callicutt earned more than 14.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 12,567 out of 14,666 | 14th |
Division Manufacturing | 4,950 out of 5,772 | 14th |
Major group Chemicals And Allied Products | 1,813 out of 2,075 | 13th |
Industry group Drugs | 1,509 out of 1,731 | 13th |
Industry Pharmaceutical Preparations | 1,168 out of 1,333 | 12th |
Source: SEC filing on April 11, 2018.
Callicutt's colleagues
We found two more compensation records of executives who worked with Jack W. Callicutt at Galectin Therapeutics in 2017.
News
Galectin Therapeutics CEO Joel Lewis' 2023 pay slips 1% to $964K
December 3, 2024
Galectin Therapeutics CEO Joel Lewis' 2022 pay slips 17% to $974K
October 6, 2023
Galectin Therapeutics CEO Joel Lewis' 2021 pay jumps 55% to $1.2M
October 17, 2022
Galectin Therapeutics CEO Harold Shlevin's 2019 pay falls 25% to $1.3M
October 19, 2020